Alaska Medicaid spending on GLP-1 drugs

How much did Alaska Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $22.2 million for GLP-1 drugs paid through Alaska Medicaid in 2025, across at least 23,249 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 102 rows of 202, so these figures are floors.

Pharmacies were reimbursed at least $5.3 million for GLP-1 drugs paid through Alaska Medicaid in 2026 (quarter 1 only, as posted so far), across at least 5,385 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 14 rows of 39, so these figures are floors.

By year and ingredient

2020at least $1,284,656No data$2,034,120at least $1,032,331at least $325,490$48,611$189,538at least $4,914,745
2021at least $4,267,285No data$1,936,019at least $2,099,702at least $234,301at least $40,707$199,551at least $8,777,565
2022at least $10,929,141at least $63,321at least $1,388,415at least $2,717,198at least $152,354at least $73,522$155,268at least $15,479,219
2023at least $16,590,119at least $826,009$1,055,501at least $2,475,354$93,625Suppressed$121,026at least $21,161,635
2024at least $19,004,242$1,756,914at least $502,037$1,599,210at least $51,006Suppressed$64,538at least $22,977,947
2025at least $17,128,855at least $3,324,040at least $209,280at least $1,453,516at least $12,027Suppressedat least $24,869at least $22,152,586
2026 (Q1)at least $3,652,370$1,313,026at least $26,428$313,301No dataSuppressedSuppressedat least $5,305,125

By product, 2025

Ozempicat least $15,956,857at least 16,95012 of 24
Rybelsusat least $1,171,998at least 1,20210 of 22
Mounjaroat least $1,945,093at least 1,85412 of 36
Zepboundat least $1,378,946at least 1,30515 of 33
Liraglutide (generic name listing)at least $190,588at least 35922 of 35
Victozaat least $18,692at least 2611 of 13
Trulicityat least $1,453,516at least 1,5148 of 24
Bydureonat least $12,027at least 151 of 2
Exenatide (generic name listing)SuppressedSuppressed2 of 2
SoliquaSuppressedSuppressed5 of 5
Xultophyat least $24,869at least 244 of 6

By quarter, 2025

Q1 2025at least $5,481,847at least 5,80612 of 36
Q2 2025at least $5,592,767at least 5,86316 of 40
Q3 2025at least $3,938,069at least 4,02938 of 62
Q4 2025at least $7,139,902at least 7,55136 of 64

By quarter, 2026 (posted so far)

Q1 2026at least $5,305,125at least 5,38514 of 39

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.